Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
Public ClinicalTrials.gov record NCT03043872. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Study identification
- NCT ID
- NCT03043872
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 987 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2017 (Actual)
- Primary completion
- Jan 27, 2020 (Actual)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Jul 16, 2026
2017 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35235 | — |
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Rogers | Arkansas | 72758 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | New Haven | Connecticut | 06520 | — |
| Research Site | Athens | Georgia | 30607 | — |
| Research Site | Fort Wayne | Indiana | 46804 | — |
| Research Site | Muncie | Indiana | 47303 | — |
| Research Site | Leawood | Kansas | 66209 | — |
| Research Site | Wichita | Kansas | 67214 | — |
| Research Site | Paducah | Kentucky | 42003 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Harrisburg | Pennsylvania | 17109 | — |
| Research Site | Sioux Falls | South Dakota | 57104 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 188 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03043872, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03043872 live on ClinicalTrials.gov.